A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
一项针对晚期实体恶性肿瘤患者的 II 期、多中心、开放标签研究，评估抗 LAG-3 抗体 ieramilimab 联合抗 PD-1 抗体 spartalizumab 的疗效。
期刊:Oncoimmunology
影响因子:6.3
doi:10.1080/2162402X.2023.2290787
Lin, Chia-Chi; Garralda, Elena; Schöffski, Patrick; Hong, David S; Siu, Lillian L; Martin, Miguel; Maur, Michela; Hui, Rina; Soo, Ross A; Chiu, Joanne; Zhang, Tian; Ma, Brigette; Kyi, Chrisann; Tan, Daniel Sw; Cassier, Philippe A; Sarantopoulos, John; Weickhardt, Andrew; Carvajal, Richard D; Spratlin, Jennifer; Esaki, Taito; Rolland, Fréderic; Akerley, Wallace; Deschler-Baier, Barbara; Rispoli, Lawrence; Samant, Tanay S; Chowdhury, Niladri Roy; Gusenleitner, Daniel; Kwak, Eunice L; Askoxylakis, Vasileios; De Braud, Filippo
